Pricing Log in Create free account
Friday 6 November 2026 Export NAMS’s income statement to Excel — free account

NewAmsterdam Pharma Company N.V.

NAMS Healthcare Biotechnology

NewAmsterdam Pharma Company N.V.’s revenue for fiscal 2025 (year ended December 2025) was $22.5 million, down 50.6% from fiscal 2024.

Revenue
+5,406.9%
EPS
+77.1%
Free cash flow
−21.8%

Quarter to September 2026, against a year earlier

18.93 0.04 +0.21%
Market cap
$2.3B
P/E
0.0×
Fwd P/E
−11.0×
Dividend yield
—
F-score
3/9
Altman Z
27.63
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

NewAmsterdam Pharma Company N.V. (NAMS) Revenue

Alert me on Revenue

NewAmsterdam Pharma Company N.V.'s revenue for fiscal 2025 was $22.5M, down 50.6% from $45.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $25.9M. NewAmsterdam Pharma Company N.V. ranks 171st of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $22.5M (50.61%)
FY2024 $45.6M 223.37%
FY2023 $14.1M (86.28%)
FY2022 $102.7M —

Quarterly newest first

Period Revenue Change
Sep 2026 $19.2M 417.81%
Jun 2026 $3.7M 21.74%
Mar 2026 $3.0M 9,400.00%
Dec 2025 $32.0K (90.80%)
11 more quarters

Revenue against peers

Company Revenue
ADMA ADMA Biologics Inc compare $519.2M
ZLAB Zai Lab Limited Unsponsored ADR compare $441.7M
XNCR Xencor, Inc. compare $105.0M
RXRX Recursion Pharmaceuticals, Inc. compare $68.2M
PVLA Palvella Therapeutics, Inc. compare $41.6M
NAMS NewAmsterdam Pharma Company N.V. $25.9M
CLDX Celldex Therapeutics, Inc. compare $887.0K
PHVS Pharvaris N.V. compare —
MBX MBX Biosciences, Inc. compare —

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on NAMS